

in partnership with:

**NHS** Oxford University Hospitals


lospitals NIF

**NIHR** Oxford Biomedical Research Centre



# The evidence-based, patient app-to-clinician system, transforming the management of diabetes in pregnancy.

Sensyne Health aims to provide regulated digital products to the NHS at an affordable price.



#### GDm-Health has been developed to support clinical services manage the increasing number of pregnant women diagnosed with diabetes.

GDm-Health is underpinned by a rich source of clinical evidence<sup>3</sup>, gathered as a result of extensive clinical evaluations.

- Electronic transfer of data
- Real-time remote transmission of BG results
- Real-time feedback and proactive outreach
- Enables prioritisation of patients
- Facilitates team-based working
- BGs and other information recorded electronically supports meaningful audit

sensynehealth.com/gdm

### Digitising the GDM care pathway

A unique collaboration between the University of Oxford (OU), the Oxford University Hospitals NHS Foundation Trust (OUH) and Sensyne Health has developed a direct patient-to-clinician blood-glucose-monitoring management system to support pregnant women with diabetes, and allowing clinicians to review real-time patient-annotated BG results submitted via a smartphone app.

## A 203 patient Randomised Controlled Trial (RCT)<sup>4</sup> showed use of GDm-Health was associated with:

- 64% reduction in pre-term births\*\*
- 16% reduction in women transitioning to pharmacological treatment\*\*
- Significantly higher patient satisfaction with care (P=.049)
- Significantly better compliance with BG monitoring increased from 61% to 80% (P<.001)
- Significant reduction in caesarean sections 27% v 46% (P=.005)

A six month comparative study of GDm-Health at Royal Surrey Hospitals NHS Trust<sup>1</sup> demonstrated transformative results, including:

- 21% reduction in mean time to intervention
- 47% reduction in the number of appointments with diabetes specialist doctors
- 100% of women using GDm-Health declared themselves happy with the care provided by the diabetes team

### The clinical and business case

NHS England has cited in its 5 Year Forward Plan<sup>5</sup> a series of priorities, which includes improvement to maternity services, as well as improving efficiency through the use of innovative technologies; delivering paperless at point of care and enabling greater patient self-management. The opportunity therefore exists to meet a number of these objectives through the adoption of GDm-Health: realising significant cost-savings through reduced hospital visits and as a direct result of potentially improving outcomes for women and babies.

This proven approach will enable clinicians to deliver better, value-based care for women and babies, contributing greatly to the future health of NHS maternity and obstetric services.

### <sup>66</sup> The GDm-Health system has helped to transform the way we deliver care for women with diabetes in pregnancy.

#### Rachel Crowley, Former Diabetes Specialist Midwife, Royal Berkshire NHS Foundation Trust

#### This product is classified as a Class I medical device that complies with the essential requirements of Directive 93/42/EEC and following amendments.

- 1 'Novel Way to Deliver Care to Women with GDM through the Use of Cloud Technology' Royal Surrey County Hospital poster presentation at Diabetes in Pregnancy conference, November 2019
- 2 Hirst JE, Mackillop L, Loerup L, Kevat DA, Bartlett K, Gibson O, Kenworthy Y, Levy JC, Tarassenko L, Farmer A. Acceptability and user satisfaction of a smartphone-based, interactive blood glucose management system in women with gestational diabetes mellitus. J Diabetes Sci Technol. 2015 Jan;9(1):111-5
- Refer to www.sensynehealth.com/gdm for full list of clinical evidence
- 4 Mackillop L, Hirst JE, Bartlett KJ, Birks JS, Clifton L, Farmer AJ, Gibson O, Kenworthy Y, Levy JC, Loerup L, Rivero-Arias O, Ming WK, Velardo C, Tarassenko L: 'Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes: Randomized Controlled Trial' JMIR Mhealth Uhealth 2018;6(3):e71
- 5 https://www.england.nhs.uk/five-year-forward-view
- \* Product images depicted are illustrative of software version 18.1. Earlier versions of the software are currently in use by UK NHS organisations.

\*\*Results did not reach statistical significance SEND<sup>TM</sup>, GDm-Health<sup>TM</sup>, EDGE<sup>TM</sup>, LIVINGSTONE<sup>®</sup>, Support-HF<sup>TM</sup> and Sensyne Health are trademarks or registered trademarks of Sensyne Health plc or its Affiliates (together 'Sensyne Health') and their licensors, in the UK and other countries. All other trademarks are the property of their respective owners.

### For more information on availability, please contact info@sensynehealth.com

Note: Not all Sensyne Health products are available in all territories, for further information contact head office.

#### www.sensynehealth.com

© 2020 Sensyne Health plc. Registered in England and Wales No. 11425451. All rights reserved. Subject to contract. Public Information. CORP-020-03